Strategy
Provided a drug company with payer, provider, and channel perspectives on the adoption of follow-on biologics in the United States; developed price and penetration scenarios for both biosimilars and "true" biogenerics
Helped a biopharmaceutical firm define and value its growth options; conducted market research and simulated (with valuation) development portfolio, market, and partnership scenarios
Evaluated and recommended drug products for development as line extensions or difficult-to-formulate generics for a drug delivery technology business
Defined growth strategies in biologic manufacturing, contract research, dosage form manufacturing and packaging, excipients, and fine chemicals